Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05535777 · ClinicalTrials.gov registry record · NA
Patient Portal Flu Vaccine Reminders_RCT 5 (LADHS)
A NA study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- NA
- Development phase
- 246,295
- Enrollment target
NCT05535777 is a NA study that has completed, run by University of California, Los Angeles. The registered enrollment target is 246,295 participants.
The verdict
NCT05535777, a NA study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- NA
- Development phase
- 246,295 participants
- Enrollment target
Study Summary
This trial is taking place in Los Angeles, CA at clinics within the Los Angeles Department of Health clinics. The study design is a comparative effectiveness trial design. Patients will be randomized into 1) receiving enhanced texting with a callback by a trained call-center staff member to schedule a vaccine visit if the patient presses "1" in response to the text, 2) receiving enhanced bidirectional texting with a texting response from a trained call-center staff member who will help the patient schedule a vaccine visit through a series of back-and-forth texts, or 3) standard text reminders (control group). Patients in all arms will receive reminders if they are due for influenza vaccine. Despite the Advisory Committee on Immunization Practices (ACIP) recommendation in 2010 that all people above 6 months of age should receive an annual flu vaccine, vaccination rates remain low: at 6m-4.9 yrs. (70%), 5-17.9 yrs. (56%), 18-64.9 yrs. (38%), and \>65 yrs. (63%). The investigators will assess the effectiveness of enhanced text R/R messages as compared to the standard of care control (standard text reminders).
Interventions
- BEHAVIORAL Enhanced texts with Callback by a Person
- BEHAVIORAL Enhanced Bidirectional Texts
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 246,295 participants |
| Start Date | 2022-09-13 |
| Est. Completion | 2023-03-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05535777
The ClinicalTrials.gov registry entry for NCT05535777 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 246,295 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Enhanced texts with Callback by a Person is the first listed.
NCT05535777 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05535777 about?
NCT05535777 is a clinical study titled "Patient Portal Flu Vaccine Reminders_RCT 5 (LADHS)". This trial is taking place in Los Angeles, CA at clinics within the Los Angeles Department of Health clinics. The study design is a comparative effectiveness trial design. Patients will be randomized into 1) receiving enhanced texting with a callback by a trained call-center staff member to schedul...
What is the current status of trial NCT05535777?
This trial is currently completed. It is a NA study. The enrollment target is 246,295 participants. The study started on 2022-09-13. Estimated completion is 2023-03-31.
What interventions are being tested in trial NCT05535777?
The interventions under investigation include: Enhanced texts with Callback by a Person (BEHAVIORAL), Enhanced Bidirectional Texts (BEHAVIORAL).
Who is sponsoring clinical trial NCT05535777?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.